CXCL10在非酒精性脂肪性肝病中的病理作用及其临床应用

发布时间：2018-04-04 12:37

本文选题：非酒精性脂肪肝　切入点：非酒精性脂肪性肝炎　出处：《河北医科大学》2016年硕士论文

【摘要】：非酒精性脂肪肝病(NAFLD)是常见的慢性肝病。NAFLD包括一系列病理改变,从单纯的脂肪变性,到非酒精性脂肪性肝炎(NASH)、肝硬化,最终可能发展为肝细胞肝癌。NASH的主要病理改变是炎症,这其中牵涉到一系列细胞因子和趋化因子。C-X-C趋化因子10(CXCL10)是一种促炎趋化因子,它在NASH的发生、发展过程中发挥重要作用。肝内CXCL10主要由肝细胞和肝窦内皮细胞分泌。CXCL10与其特异性受体CXCR3结合,募集活化的CXCR3+T淋巴细胞和巨噬细胞聚集至肝实质,起到促进炎症、细胞凋亡和纤维化的作用。血清CXCL10水平与小叶炎症的严重程度相关,且为NASH的独立危险因素。CXCL10可以作为NASH的无创性生物标记物,并且可能是NASH的潜在的治疗靶点。本文分析了CXCL10在非酒精性脂肪性肝病中的病理作用及其潜在的临床应用价值,为进一步CXCL10在改善NASH和相关代谢性疾病中的作用提高理论基础。
[Abstract]:This involves a series of cytokines and chemokines. C-X-C chemokine 10CXCL10) is a pro-inflammatory chemokine, which plays an important role in the occurrence and development of NASH.CXCL10 in liver is mainly secreted by hepatocytes and sinusoidal endothelial cells. CXCL10 binds to its specific receptor CXCR3, and collects activated CXCR3 T lymphocytes and macrophages into the liver parenchyma, which can promote inflammation, apoptosis and fibrosis.Serum CXCL10 level is correlated with the severity of lobular inflammation and is an independent risk factor for NASH. CXCL10 can be used as a noninvasive biomarker of NASH and may be a potential therapeutic target for NASH.This paper analyzes the pathological role of CXCL10 in non-alcoholic fatty liver disease and its potential clinical application value, which is the theoretical basis for further improving the role of CXCL10 in the improvement of NASH and related metabolic diseases.
【学位授予单位】：河北医科大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R575.5

【参考文献】